This study provides real-world evidence for immunotherapy strategies in relapsed follicular lymphoma, supporting the feasibility and tolerability of CD20×CD3 bispecific antibody-based T-cell redirecting therapy after failure of multiple lines of treatment, offering direct reference for subsequent clinical pathway design.
Literature Overview
The article 'Safety and Efficacy of Mosunetuzumab: Experience in the Hospital Cardinale Giovanni Panico,' published in the journal Antibodies, systematically investigates the efficacy and safety of the bispecific antibody mosunetuzumab in the treatment of relapsed or refractory follicular lymphoma (FL) within real-world clinical practice. The study retrospectively reviewed three patients treated with this agent, all of whom achieved complete response after failing multiple prior therapies, with manageable toxicity. These findings further validate the therapeutic potential of mosunetuzumab in advanced B-cell non-Hodgkin lymphoma.Background Knowledge
Follicular lymphoma (FL) is a common indolent B-cell non-Hodgkin lymphoma. Although initial treatment responses are generally favorable, most patients experience recurrent relapses, particularly after early progression or transformation to high tumor burden, leading to significantly worse outcomes. First-line therapy typically involves anti-CD20 monoclonal antibodies combined with chemotherapy, such as R-CHOP or BR regimens, but some patients are either resistant or intolerant to these treatments. As the number of prior therapies increases, the duration of response progressively shortens, creating an urgent need for novel therapeutic strategies. Bispecific antibodies such as mosunetuzumab simultaneously bind CD20 (expressed on B cells) and CD3 (expressed on T cells), enabling T-cell-mediated targeted killing of malignant B cells, thereby overcoming limitations of conventional therapies. However, further validation is needed regarding the stability of efficacy, toxicity management, and optimal patient selection in real-world settings. This study addresses these gaps through retrospective analysis, evaluating the performance of mosunetuzumab in actual clinical practice and providing critical data to optimize post-line treatment pathways for FL.
Research Methods and Experiments
The study was conducted at the Card. G. Panico Hospital in Italy and included patients with relapsed or refractory FL who received mosunetuzumab treatment starting in 2022. The drug was administered via intravenous infusion in 21-day cycles, with a stepwise dose escalation in the first cycle (1 mg → 2 mg → 60 mg) to mitigate cytokine release syndrome (CRS) risk, and the initial dose was administered under hospital supervision. Efficacy was assessed using PET/CT imaging, with the primary endpoint being complete metabolic response (CMR). Safety was evaluated based on adverse event reporting. The study provides detailed case descriptions of three patients who completed treatment, all of whom had failed at least two prior systemic therapies, including previous regimens such as R-CHOP, R-Benda, ASCT, or R-DHAP.Key Conclusions and Perspectives
Research Significance and Prospects
This study confirms the high efficacy and manageable toxicity of mosunetuzumab in real-world settings, offering a new treatment option for patients with relapsed/refractory FL, particularly those ineligible for CAR-T therapy. Its fixed-duration treatment regimen is more accessible than the personalized manufacturing required for CAR-T, making it a potential standard post-line therapy.
From a drug development perspective, this study supports further exploration of combination strategies involving bispecific antibodies and other immunotherapies (e.g., PD-1 inhibitors) or targeted agents (e.g., BTK inhibitors) to enhance depth and durability of response. Additionally, more precise biomarker systems are needed to predict CRS risk and treatment response, thereby optimizing patient selection.
In terms of clinical monitoring, enhanced surveillance for CRS and ICANS—especially during the first cycle—is warranted to ensure timely intervention. Furthermore, long-term follow-up data are still needed to assess potential late-onset infections or immune reconstitution abnormalities.
Conclusion
This study, based on clinical observations of three patients with relapsed/refractory follicular lymphoma, confirms the high efficacy and favorable tolerability of the bispecific antibody mosunetuzumab in real-world settings. All patients achieved complete metabolic remission after multiple prior treatment failures, maintained remission during follow-up, and experienced no severe neurotoxicity, with only mild cytokine release syndrome observed. These results not only validate findings from global clinical trials but also underscore the feasibility of this therapy in routine clinical practice. From bench to bedside, CD20×CD3 bispecific antibodies represent a significant advancement in T-cell redirecting immunotherapy, offering a fixed-duration, off-the-shelf immunotherapeutic option for patients with indolent lymphoma without the need for ex vivo manufacturing. Future research should focus on optimizing dosing regimens, identifying predictive biomarkers, and exploring combination therapies to further improve outcomes. This study establishes a solid foundation for the post-line treatment paradigm in follicular lymphoma, with the potential to significantly improve long-term survival and quality of life for patients.
